7 news items
Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)
ATXI
FBIO
16 May 24
and assumptions that are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted
Avenue Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
ATXI
FBIO
15 May 24
and results may differ materially from what is expressed or forecasted in, or implied by, the forward-looking statements due to numerous risks
Avenue Therapeutics Announces Reverse Stock Split
ATXI
FBIO
24 Apr 24
may differ materially from what is expressed or forecasted in, or implied by, the forward-looking statements due to numerous risks and uncertainties
Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024
ATXI
FBIO
25 Mar 24
and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may differ materially from what
Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights
ATXI
FBIO
18 Mar 24
and assumptions that are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in, or implied
4cowwodznvn hm
ATXI
FBIO
15 Mar 24
that are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in, or implied
u97pwd77kpqof0a4adg2kf7x4w3zxjq
ATXI
FBIO
11 Mar 24
. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in, or implied by, the forward-looking statements due
- Prev
- 1
- Next